GSK news

GlaxoSmithKline (GSK) today announced the submission of a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMEA) for pazopanib as an oral therapy for patients with advanced and/or metastatic renal cell carcinoma (RCC).

GlaxoSmithKline today announced initiation and dosing of the first patient of the Phase III clinical trial programme to evaluate the efficacy, safety and tolerability of the investigational GLP-1 (Glucagon-like peptide 1) agonist Syncria® (albiglutide) in men and women with type 2 diabetes.

GlaxoSmithKline and Idenix Pharmaceuticals, Inc.today announced the execution of a license agreement granting GSK exclusive worldwide rights to IDX899.

GlaxoSmithKline and Genmab A/S announced today the submission of a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMEA) for Arzerra™ (ofatumumab) for the treatment of chronic lymphocytic leukaemia (CLL).

GSK delivers EPS of 104.7p before major restructuring. Dividend increased 8% to 57p

- Data increase confidence in the Horizon development programme

GlaxoSmithKline is a leading healthcare company that helps people to do more, feel better and live longer. This RSS feed contains press releases and investor news.